Ocugen (NASDAQ: OCGN) — Perfil da empresa, notícias e dados financeiros
Ocugen is a biopharmaceutical company developing gene therapies for blindness and a COVID-19 vaccine, focused on innovative research.
Ocugen
Ocugen (NASDAQ:OCGN) is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The company's diverse portfolio reflects its mission to address a broad spectrum of eye diseases with its breakthrough therapies. In the realm of vaccines, Ocugen has garnered attention for its partnership to develop Covaxin, a COVID-19 vaccine candidate, aimed at providing a solution for the global pandemic. The company is committed to innovative research and solutions that could potentially redefine treatments for patients worldwide. With an unwavering focus on addressing unmet medical needs, Ocugen's diverse project pipeline positions the company as a hopeful contender in the fight against both common and rare diseases.
Resumo
Operações
Produtos e/ou serviços de Ocugen
- Covaxin, a COVID-19 vaccine developed with Bharat Biotech, aimed at enhancing global vaccine availability.
- Gene therapy products targeting retinal diseases, with a focus on rare and under-treated conditions.
- Modifier gene therapy platform to address multiple retinal diseases, aiming at broader therapeutic applications.
- A portfolio of biologic therapies for eye diseases, leveraging new technology to improve ocular health.
- Developing novel biologic treatments for eye diseases, with an emphasis on innovative delivery mechanisms and formulations.
- Advanced research in immune modulator treatments for eye diseases, exploring new pathways for ocular therapy.
equipe executiva do Ocugen
- Shankar MusunuriCo-Founder, CEO & Chairman
- Arun UpadhyayChief Scientific Officer and Head of Research & Development
- Rita Johnson-GreeneCFO & Principal Accounting Officer
- Paul StaidExecutive Vice President of Operations
- John KouchGeneral Counsel
- Chris ClarkVP of Corporate Communications
- Kristen CraftHead of People & Culture
- Vijay TammaraChief Development Officer
- Mohamed GeneadChief Medical Officer
- Jyothy PillaiVP & Head of Regulatory & Quality
Últimas notícias sobre a Ocugen
Ocugen licenses OCU400 rights for $255 million
United StatesOcugen receives OCU400 priority designation in Bahamas
United StatesOcugen signs OCU400 MENA license agreement
United StatesOcugen reports positive 12-Month phase 2 ArMaDa results for geographic atrophy
United StatesOcugen reports Q4 net loss of $17.7M with FY loss reaching $67.8M
United StatesOcugen completes Phase 3 enrollment for gene-agnostic retinitis pigmentosa therapy
United States
Principais indicadores financeiros
Resultados divulgados pela Ocugen, em USD.
- Cap. de mercado
- 256,8 mi
- Receita (TTM)
- 4,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,4 mi | -62,9 mi | -67,8 mi | |
| 4,1 mi | -54,8 mi | -54,1 mi | |
| 6 mi | -65,5 mi | -63,1 mi | |
| 2,5 mi | -84,9 mi | -77,8 mi |